<DOC>
	<DOCNO>NCT00363779</DOCNO>
	<brief_summary>Background : - Large granular lymphocyte ( LGL ) leukemia low-grade non-Hodgkin 's lymphoma . - LGL associate low number white blood cell ( lead recur infection ) , red blood cell ( cause anemia ) platelet ( cause abnormal bleed ) . - Cyclosporine ( CSA ) immunosuppressive drug improves low blood cell count 50 percent patient LGL leukemia . Objectives : - To identify factor determine cyclosporine work patient others . - To identify cause low blood count LGL leukemia . Eligibility : Patients 18 year age old LGL leukemia . Design : - Patients medical history , physical examination blood test , bone marrow biopsy x-ray study , include chest x-rays compute tomography ( CT ) scan chest , abdomen pelvis . Patients easily accessible enlarge lymph node node biopsy ( removal small piece tissue microscopic examination ) . - Patients take cyclosporine twice day mouth . Blood sample take least weekly adjust cyclosporine dose maintain therapeutic serum level . - Patients undergo apheresis ( collection white blood cell ) number different time point study ( maximum 6 time ) look difference leukemia cell treatment cyclosporine . For apheresis , blood withdrawn needle arm vein direct catheter ( plastic tube ) machine separate component . The white cell extract rest blood return needle second needle arm .</brief_summary>
	<brief_title>Effect Cyclosporine Therapy Gene Expression Patients With Large Granular Lymphocyte Leukemia</brief_title>
	<detailed_description>Background : - LGL leukemia low grade non-Hodgkins Lymphoma characterize tissue invasion marrow , spleen liver - Recurrent infection due chronic neutropenia transfusion-dependent anemia principal cause initiation therapy - Approximately 50 % patient treat cyclosporine ( CSA ) respond treatment . CSA appear correct associate cytopenia without decrease LGL number , suggest may inhibit LGL secretion yet unidentified mediator neutropenia anemia . - Analysis differential gene expression profile patient LGL leukemia treat cyclosporine potential detect yet unidentified , therapeutic target possibly provide predictor CSA responsiveness . Objective : - Identify change gene expression pattern induce cyclosporine therapy patient LGL leukemia - Identify difference respond non-responding patient Eligibility : -Patients Large Granular Lymphocyte leukemia Design : - Patients treated cyclosporine dose 5-10mg/kg/day divided dos , dos adjust maintain therapeutic serum level 200-400ng/ml . These therapeutic level shall maintain 3 month . - Tumor response evaluate 3 month therapy , dose CsA may taper require sustain response discontinue evidence response , relapse . - Blood sample Lymphapheresis collection circulate malignant cell perform number different time point . Gene expression profile carry Affymetrix microarrays compare pretreatment post-treatment sample .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . All patient must histologic cytologic diagnosis Tcell LGL leukemia determine Laboratory Pathology Hematology Clinical Center , National Institutes Health 2 . All patient must hemocytopenias granulocyte count less 1,200/ul , platelet count le 100,000/ul hemoglobin less 10 g/dl , require hematopoietic support ( transfusion colony stimulate factor ) maintain count high level . 3 . Patients must measurable evaluable disease 4 . Patients must creatinine less 2.0 mg/dl . 5 . Omission cytotoxic chemotherapy 3 week prior entry trial require . However , patient receive stable corticosteroid eligible . 6 . Age great 18 year 7 . Karnofsky performance great 70 % 8 . Patients must life expectancy great 3 month . 9 . Patients must able understand sign Informed Consent form . 10 . All female patient must use adequate contraception participation trial three month complete therapy . EXCLUSION CRITERIA : 1 . Patients uncontrolled hypertension 2 . Pregnant nursing patient eligible study CSA cross placenta . Based clinical use , premature birth low birth weight consistently observe . Breastfeeding contraindicate CSA enters blood milk may possibly administer child . 3 . Underlying immunodeficiency state include human immunodeficiency virus ( HIV ) seropositivity . 4 . Positive antibody hepatitis C positive hepatitis B surface antigen , 5 . Patients serious intercurrent illness , concurrent hepatic , renal , cardiac , neurologic , pulmonary , infectious metabolic disease severity would preclude patient ' ability tolerate cyclosporine . 6 . Patients receive cyclosporine LGL leukemia previously fail respond .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Large Granular Lymphocyte ( LGL )</keyword>
	<keyword>LGL</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Cyclosporine</keyword>
	<keyword>Microarray</keyword>
	<keyword>Gene Expression</keyword>
	<keyword>Cyclosporin</keyword>
	<keyword>Large Granular Lymphocyte Leukemia</keyword>
	<keyword>LGL Leukemia</keyword>
</DOC>